Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial

Table 1

The demographic and background features of patients.

Variables	Control	Treatment	value
Age (years)	53.9 ± 11.9	54.6 ± 13.4	0.813
Gender
Male	24 (61.5%)	11 (37%)	0.054
Female	15 (38.5%)	18 (63%)	0.887
Body mass index (kg/m^2)	30.4 ± 12.3	27.86 ± 4.6	0.579
Hospitalization duration (days)	5.75 ± 3.27	5.40 ± 1.52	0.623
Diabetes mellitus	10 (25.6%)	7 (24.1%)	0.479
Hypertension	11 (28.2%)	6 (20.7%)	0.292
Dyslipidemia	11 (28.2%)	5 (17.2%)	0.611
Cardiovascular diseases	5 (12.8%)	5 (17.2%)	0.583
Rheumatoid arthritis	4 (10.3%)	2 (6.8%)	0.583

Independent t-test; Pearson’s chi-squared test.